PFE Pfizer Inc.
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Company profile
Ticker
PFE
Exchange
CEO
Albert Bourla
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
PFE stock data
()
Calendar
8 Aug 19
23 Oct 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 13.26B | 13.12B | 13.98B | 13.3B | |
| Net income | 5.05B | 3.88B | -393M | 4.11B | |
| Diluted EPS | 0.89 | 0.68 | -0.05 | 0.69 | |
| Net profit margin | 38.04% | 29.61% | -2.81% | 30.94% | |
| Operating income* | 4.52B | 4.68B | -588M | 4.48B | |
| Net change in cash | -153M | 798M | -2.42B | 855M | |
| Cash on hand | 1.78B | 1.94B | 1.14B | 3.56B | |
| Cost of revenue | 2.58B | 2.43B | 3.08B | 2.69B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 53.65B | 52.55B | 52.82B | ||
| Net income | 11.15B | 21.31B | 7.22B | 6.96B | |
| Diluted EPS | 1.87 | 3.52 | 1.17 | 1.11 | |
| Net profit margin | 20.79% | 40.55% | 13.66% | ||
| Operating income* | 13.17B | 13.53B | 9.51B | 10.14B | |
| Net change in cash | -203M | -1.25B | -1.05B | 298M | |
| Cash on hand | 1.14B | 1.34B | 2.6B | 3.64B | |
| Cost of revenue | 11.25B | 11.23B | 12.32B | 9.65B |
Financial data from Pfizer earnings reports. *Asterisk values are approximate.
Financial report summary
?Competition
Akorn • TherapeuticsMD • GT Biopharma • Church & Dwight • Teligent • Cypress Bioscience • Celldex Therapeutics • Poniard Pharmaceuticals • Imclone Systems • Acura Pharmaceuticals
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
AA, acid, andNew, Array, Aurobindo, boxed, bridge, CDK, cervical, cognitive, Colorado, conclusion, confirmed, consumption, contemplated, coupon, CreditWatch, decade, dilated, dual, Endothelial, enterprise, equate, excellence, formation, FORMSFOR, FTC, glioblastoma, hepatocellular, Hurricane, Inline, instance, Lamin, Les, lungcancer, lymphocytic, lymphoma, Maria, mCRC, microscopic, mitigate, notably, notch, NRDL, obligor, opioid, page, patientswith, pembrolizumab, potency, Presidential, pro, protein, rata, RCC, RESET, SAS, secondary, selectin, simultaneously, SmPC, strongest, symptomatic, TEC, thehead, transform, triple, underwritten, Vascular, VEGFR, vigorously, wholly, XBRL
Removed:
accompanied, adenocarcinoma, agent, aggressively, alfa, Amgen, antirheumatic, Apixaban, appealing, Asian, bleeding, Blueprint, bolivar, closely, communicate, communicated, consistent, conventional, de, death, DICOM, divested, EEA, epoetin, Epogen, exert, filgrastim, gastric, gastroesophageal, head, improvement, inadequate, Inspector, intolerant, limiting, long, medicinal, methotrexate, mixed, moderately, Neupogen, neuromuscular, neuroscience, observed, occurred, ovarian, overexpressing, Panel, partner, pharmacy, priced, Procrit, publish, RAR, recover, reducing, released, revalue, talazoparib, tanezumab, Trump, vehicle, vote, wrongful
Financial reports
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K
2017 FY
Annual report
22 Feb 18
10-Q
2017 Q3
Quarterly report
9 Nov 17
10-Q
2017 Q2
Quarterly report
10 Aug 17
10-Q
2017 Q1
Quarterly report
11 May 17
Current reports
8-K
Departure of Directors or Certain Officers
27 Sep 19
8-K
Pfizer Announces Closing of Joint Venture with Glaxosmithkline to Create a Premier Global Consumer Healthcare Company
5 Aug 19
8-K
Pfizer Reports Second-quarter 2019 Results
29 Jul 19
8-K
Entry into a Material Definitive Agreement
29 Jul 19
8-K
Scott Gottlieb Elected to Pfizer’s Board of Directors
27 Jun 19
8-K
Regulation FD Disclosure
17 Jun 19
8-K
Pfizer Reports First-quarter 2019 Results
30 Apr 19
8-K
Submission of Matters to a Vote of Security Holders
29 Apr 19
8-K
Other Events
11 Mar 19
8-K
Pfizer Prices $5,000,000,000 Debt Offering
6 Mar 19
Registration and prospectus
425
Business combination disclosure
10 Sep 19
425
Business combination disclosure
4 Sep 19
425
Business combination disclosure
30 Aug 19
S-8
Registration of securities for employees
9 Aug 19
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 19
425
Business combination disclosure
2 Aug 19
425
Business combination disclosure
1 Aug 19
425
Business combination disclosure
31 Jul 19
425
Business combination disclosure
30 Jul 19
425
Business combination disclosure
30 Jul 19
Proxies
PX14A6G
Letter to shareholders
8 Apr 19
DEFA14A
Additional proxy soliciting materials
2 Apr 19
PX14A6G
Letter to shareholders
21 Mar 19
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEF 14A
Definitive proxy
14 Mar 19
PX14A6G
Letter to shareholders
18 Apr 18
DEFA14A
Additional proxy soliciting materials
6 Apr 18
PX14A6G
Letter to shareholders
6 Apr 18
DEF 14A
Definitive proxy
15 Mar 18
DEFA14A
Additional proxy soliciting materials
15 Mar 18
Other
CT ORDER
Confidential treatment order
15 Mar 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
7 Mar 17
NO ACT
No action letter
10 Feb 17
NO ACT
No action letter
31 Jan 17
NO ACT
No action letter
26 Jan 17
NO ACT
No action letter
10 Jan 17
NO ACT
No action letter
27 Dec 16
SD
Conflict minerals disclosure
31 May 16
Patents
GRANT
Utility
Sulfonyl amide derivatives for the treatment of abnormal cell growth
22 Oct 19
Inventors: Michael J. Luzzio, Kevin D. Freeman-Cook, Samit K. Bhattacharya, Matthew M. Hayward, Catherine A. Hulford, Christopher L. Autry, Xumiao Zhao, Jun Xiao, Kendra L. Nelson
APP
Utility
Novel Pyrimidine Carboxamides As Inhibitors of VANIN-1 Enzyme
17 Oct 19
Inventors: Agustin Casimiro-Garcia, Joseph Walter Strohbach, David Hepworth, Frank Eldridge Lovering, Chulho Choi, Christophe Philippe Allais, Stephen Wayne Wright
APP
Utility
Stable Liquid Antibody Formulation
17 Oct 19
The present invention relates generally to the field of pharmaceutical formulations of antibodies.
APP
Utility
6,7-DIHYDRO-5H-PYRAZOLO[5,1-B][1,3]OXAZINE-2-CARBOXAMIDE Compounds
3 Oct 19
Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Matthew Merrill Hayward
APP
Utility
Antibodies to MAdCAM
3 Oct 19
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM.